The effect of apatinib combined with chemotherapy or targeted therapy on non‐small cell lung cancer in vitro and vivo

Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma

(2018) Wen-Chang Yu et al.   MEDICINE

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study

(2018) Miaomiao Gou et al.   Scientific Reports

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

(2018) Baohui Han et al.   JAMA Oncology

Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance

(2017) Fang Li et al.   EUROPEAN JOURNAL OF CANCER

Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ

(2017) Wen-Ying Lee et al.   INTERNATIONAL JOURNAL OF CANCER

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro

(2017) Xiuli Feng et al.   Oncotarget

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma

(2017) Qiu-Xia Peng et al.   Oncotarget

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives

(2016) Vivek Asati et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

(2015) Caicun Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

(2015) Sara M. Tolaney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer therapy and cardiovascular risk: focus on bevacizumab

(2015) Panagiota Economopoulou et al.   Cancer Management and Research

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

(2013) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

(2011) Shu Tian et al.   CANCER SCIENCE

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters

(2010) Y.-j. Mi et al.   CANCER RESEARCH

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH